Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 GeneticVariation disease BEFREE Positive expression of Lin28 was associated with lymph node metastases (<i>P</i><0.001), HER-2 (<i>P</i>=0.024), estrogen receptor (<i>P</i>=0.039), and progesterone receptor (<i>P</i>=0.027). 30799940 2019
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Overexpression of moesin was significantly associated with advanced clinical stage (P=0.002), positive lymph node metastasis (P<0.0001), and estrogen receptor (ER; P=0.008) and progesterone receptor (P=0.026) status. 30675256 2019
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Lymph node metastasis and progesterone receptor negativity had borderline significance in this regard (HR = 1.741 and 1.638, <i>p</i> = 0.099 and 0.061). 31598339 2019
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Compared with ER or PR positive patients (n=868), patients with ER/PR loss (n=35) had deeper myometrial infiltration (p=0.012), severer FIGO stage (p=0.004), and higher rate of pelvic lymph node metastasis (p=0.020). 30479097 2019
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE <b>Result:</b> Age, race, tumour size, tumour primary site, pathological grade, oestrogen receptor (ER) status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER2) status were independent predictive factors of positive lymph node metastasis in T1 breast cancer. 31258749 2019
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Whereas T allele was positively correlated with histopathological grade (Tau-b=0.29; p=0.03) and lymph node metastasis (Tau-b=0.35; p=0.02) in ER/PR<sup>+</sup>HER2<sup>+</sup>BCs and with Ki67 (Tau-b=0.51; p=0.008) in ER<sup>-</sup>PR<sup>-</sup>HER2<sup>+</sup> subgroup. 28964592 2018
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Chemerin expression was significantly correlated with weight (<i>r</i>=0.256, <i>P</i>=0.04), body mass index (<i>r</i>=0.233, <i>P</i>=0.03), tumor size (<i>r</i>=0.235, <i>P</i>=0.03), lymph node metastasis (<i>r</i>=0.265, <i>P</i>=0.045), distant metastasis (<i>r</i>=0.267, <i>P</i>=0.02), and tumor grading, (<i>r</i>=0.421, <i>P</i>=0.004), while it was inversely significantly correlated with estrogen receptor and progesterone receptor expression in malignant breast tissues (<i>P</i>=0.038, <i>r</i>=-0.437, and <i>P</i>=0.047, <i>r</i>=-0.316), respectively. 30498371 2018
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 AlteredExpression disease BEFREE Expression of ECT2 in breast cancer was significantly higher than that of the normal control group (p<0.001), and it was related to tumour grade, the status of lymph node metastasis, TNM staging, recurrence status, menopausal status, and the Ki-67 proliferation index (p<0.05), and not related to age, tumour size, tumour type, expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2, and triple-negative disease (p>0.05). 29051317 2018
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Univariate analysis showed that SUV<sub>max</sub> (p = 0.0054), MTV (p = 0.0054), TLG (p < 0.0001), tumor size (p = 0.0083), estrogen receptor negativity (p = 0.046), progesterone receptor negativity (p = 0.0023), human epidermal growth factor receptor 2 positivity (p = 0.043), and the presence of axillary lymph node metastasis (p = 0.0037) were also significantly associated with recurrence. 29134565 2018
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE We analyzed the estrogen receptor (ER), progesterone receptor (PR), and HER2 status and Ki67 index in 41 primary unifocal (PU) and 37 primary multiple (PM) breast carcinomas with identical immunohistochemical profiles among multiple tumor foci and the matched axillary lymph node metastases. 28099174 2018
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 GeneticVariation disease BEFREE Furthermore, when compared with the clinical parameters, the significant association was found between the promoter hypermethylation and lymph node metastasis ( p ≤ 0.001), tumor stage ( p = 0.039), tumor grade ( p = 0.028), estrogen receptor status ( p = 0.018), and progesterone receptor status ( p = 0.046). 28443466 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Axillary lymph node metastasis and progesterone receptor (PR) status were significantly different between the endocrine therapy alone group and the chemotherapy group in terms of OS. 28562530 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 AlteredExpression disease BEFREE Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. 28416639 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE A higher TBR value was significantly correlated with tumor size ≥ 2 cm (P = 0.001), axillary lymph node metastasis (P = 0.007), high HG (P = 0.029), negative PR status (P = 0.036), and Ki-67 ≥ 14% (P = 0.007). 28480663 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE The tumors in Group II were more likely to be larger (P < 0.0001), higher grade (P = 0.0029), estrogen receptor (ER)+/progesterone receptor (PR)- (P = 0.0319), and human epidermal growth factor receptor 2 (HER-2)-positive (P < 0.0001), and to have axillary lymph node metastasis (P = 0.0033) than those in Group I. 28770448 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 GeneticVariation disease BEFREE The linc-ROR expression levels in plasma were correlated with lymph node metastasis (P< 0.05), estrogen receptor (ER) (P< 0.05) and progesterone receptor (PR) (P< 0.05). 28869448 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 AlteredExpression disease BEFREE The meta-analysis indicated that breast cancers with PTEN loss were significantly associated with the tumor size ≥2 cm group (ORFEM = 1.68, 95%CIFEM [1.34, 2.10]), negative expression of estrogen receptor (ORREM = 1.95, 95%CIREM [1.09, 3.49]), negative expression of progesterone receptor (ORFEM = 1.72, 95%CIFEM [1.43, 2.08]), the advanced stage (ORREM = 1.94, 95%CIREM [1.35, 2.80]), positive axillary lymph node metastasis (ORREM = 1.80, 95%CIREM [1.30, 2.50]), and the local recurrence (ORFEM = 1.70, 95%CIFEM [1.26, 2.28]). 28885360 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE However, breast cancer was not significantly correlated with lymph node metastasis (OR = 1.19, 95%CI = 0.83 - 1.70, P = 0.35), Progesterone Receptor (PR) status (OR = 1.08, 95%CI = 0.58 - 2.00, P = 0.81), Human epidermal growth factor receptor - 2(HER-2/neu)status (OR = 1.01, 95%CI = 0.65 - 1.57, P = 0.97), P53 mutation (OR = 1.30, 95%CI = 0.76 - 2.21, P = 0.34) and age > 50 (OR = 1.07, 95%CI = 0.46 - 2.51, P = 0.88). 28848211 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE Furthermore, DCISM was associated with more aggressive tumor characteristics like higher rates of oestrogen receptor (ER) and progesterone receptor (PR) negativity, HER2 positivity, and lymph node metastasis. 28165014 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 AlteredExpression disease BEFREE Furthermore, LAMP1 protein expression levels were significantly associated with histological grade (P=0.047), estrogen receptor expression (P=0.003), progesterone receptor expression (P=0.002), molecular classification (P=0.022), lymph node metastasis (P=0.033) and tumor-node-metastasis (TNM) stage (P=0.012). 29085473 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE The results showed a significant association between overexpression of CD133 and estrogen receptor status (OR 0.35, 95% CI 0.18-0.70), progesterone receptor status (OR 0.56, 95% CI 0.43-0.74), human epidermal growth factor-2 status (OR 1.81, 95% CI 1.33-2.45), lymph node metastasis (OR 1.98, 95% CI 1.34-2.92), and tumor histological grade (OR 1.79, 95% CI 1.26-2.54) in breast cancer. 28243121 2017
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE The results revealed that the expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls (P< 0.05), and plasma H19 levels were significantly correlated with estrogen receptor (ER) (P= 0.008), progesterone receptor (PR) (P= 0.025), c-erbB-2 (P= 0.043) and lymph node metastasis (P= 0.006). 27540977 2016
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE LOH in THRB was associated with negative estrogen receptor (ER), negative progesterone receptor (PR), both negative estrogen receptor and progesterone receptor (HR) and human epidermal growth factor receptor-2 (HER2) and lymph node metastasis (p = 0.0001, p = 0.005, p = 0.001 and p = 0.018). 26350179 2016
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 Biomarker disease BEFREE In regard to clinicopathological variables, it was demonstrated that the CT and CC genotype were associated with tumor size, lymph node metastasis and progesterone receptor status. 26986853 2016
Entrez Id: 5241
Gene Symbol: PGR
PGR
0.100 GeneticVariation disease BEFREE When stratified by clinicopathologic features, the T allele of rs2294008 was associated with progesterone receptor status (homozygote model, OR: 1.98, 95% CI: 1.08-3.63; recessive, OR: 1.87, 95% CI: 1.04-3.37), and the rs2976392 polymorphism was associated with high lymph node metastasis risk in homozygote model (OR: 2.09, 95%CI: 1.01-4.31). 27050280 2016